Category Archives: Technology

BREAKING: HILLARY CLINTON RELEASES ALL EMAILS FROM HER PERSONAL ACCOUNT

image
Photo credit: peterdaou.com

WASHINGTON, D.C. (The Adobo Chronicles) – Bowing to intense pressure, and to clear the air once and for all about the use of her personal email account for official communication during her term as Secretary of State, Hillary Clinton today released all of her email records to the media.

Political opponents and reporters,  especially from FOX News, scrambled to read and scrutinize the tens of thousands of email messages that Clinton released and were very disappointed that there was not a single email that could constitute a ‘political bomb.’

Most of the emails were addressed to U.S. ambassadors in foreign countries which she had visited, informing them of her flight arrival and duration of her visits.  The rest were personal notes to Bill Clinton, asking the former president to make dinner arrangements at their favorite restaurants in Washington, D.C. and New York.  There were a few emails sent to Barbara Streisand asking her how she was doing, and one email to Monica Lewinsky wishing her the best in her tell-all book endeavor.

Now, Republicans, who were counting on the email issue to become as explosive as Watergate and the Iran Contra Affair, are instead dealing with a far greater political fallout resulting from the open letter to Iran signed by 47 of their colleagues in the Senate.

Guess who’s having the last laugh?

FACEBOOK PLATINUM DEBUTS IN THE U.S., BY SUBSCRIPTION ONLY

imageMENLO PARK, California  (The Adobo Chronicles) – You’ve probably wondered why many of your friends or family have not been liking, or responding to, your Facebook posts. Well, it’s because they’re not seeing it.

By some kind of algorithm, Facebook determines who gets to see your posts, and it’s not a whole lot, unless, of course, you boost your posts by paying some dollars. You can complain all you want, but business is business. Like everyone else, Facebook has to make some money, right?

But there is some good news for netizens in the U.S. This weekend, Facebook will launch Facebook Platinum, which, if you subscribe to it, will increase the number of people that will see your posts. But it is not free.

Platinum subscription will cost you $100 per month, but you can be assured that every single post from you will reach a minimum of 5,000 people, whether or not they’re your FB friends. The Platinum version will only be available in the U.S.  Facebook says it will consider offering this premium service to other countries depending on how well this new initiative is received in America.

So, watch out for your invitation to subscribe to Facebook Platinum.  And once you have it, don’t leave home without it!

FDA APPROVES FIRST ‘SELFIE’ DRUG

imageLENERKUSEN, NORTH RHINE-WESTPHALIA, Germany (The Adobo Chronicles) – The U.S. Food and Drug Administration (FDA) has given the green light to Bayer Pharmaceuticals for the marketing of the first drug to cure selfitis, an inflammation of the ego which last year was officially declared a mental disorder by the American Psychiatric Association.

Bayer is a German chemical and pharmaceutical company founded in Barmen, Germany in 1863. It is headquartered in Leverkusen, North Rhine-Westphalia, Germany and well is known for its original brand of aspirin.

The FDA approval came after successful Phase III clinical trials which showed the new pill’s overwhelming safety and efficacy in combatting selfies – the taking of photos of one’s self and posting them on social media.

Because selfitis has become a highly contagious worldwide epidemic, the FDA granted Bayer a fast track approval process. FDA drug approval takes takes anywhere from 10 to 15 years, but it took just 14 months for Bayer to gain the marketing green light.

The new drug comes in pill form and requires a doctor’s prescription. Dosage is different for men and women.  Men need to take one pill a day while women need 5  pills.  Neither Bayer nor the FDA had any explanation on the dosage discrepancy.

Bayer is now pursuing drug approval in Europe and Asia.